When the future of ADCs and bispecifics collide
How to stand out from the early-stage competition
A busy and long weekend of data at ESMO24!
On biomarkers, acquired resistance and immune escape, oh my!
What can we learn from the initial LBA abstract titles?
Finding targets for combinatorial therapy to combat cancer resistance
Which combinations make rational sense and which might see action in the clinic?
The good, the bad and the ughly from ESMO24
A look atfive recent developments and what we can learn from them
Where is the ADC space heading and waht issues need to be addressed?
Early stage oncology new product development is a rather strange beast at times. On the one hand is the…
How pivoting therapy areas might make a real impact for several refractory diseases
Who's going to be roaring forward?
Teasing out relevant markers and learning more about what patients tumours are telling us is key
Will degrading BTK work – even in patients who received prior inhibitor therapy?
In beast mode – or not?
A vertical and horizontal fishing expedition in new product development
In our fifth preview from the AACR annual meeting being held in San Diego next month, we noticed some…
The good, the bad, and the ugly under belly of the next flurry of ADCs
W2W4 - what to watch for in an emerging oncology niche
What happens when multiple oncogenic pathways converge at the crossroads? An important aspect to watch out for heading into AACR24
Finding the right cell/right compartment isn't easy - it requires persistence and dedication
Where we look at half a dozen emerging agents and put them through their paces
A twist in the ADC moiety to think about
Our take on data from half a dozen key trials at ASCO GI24
It's time to look to the future beyond plain vanilla ADCs
What's next beyond BTK inhibition in lymphomas and CLL?
Pulling disparate sources together to develop a more optimised approach to targeting oncoproteins
Eight key areas to watch out for at SITC 2023!
Out of the ashes, a new phoenix can rise
What to watch out for in DDR, epigenetic therapies, and other hot topics
From epigenetics to SHP2, a look at various upcoming presentations this month
From CAR-T cells to protein degradation
Early-stage agents in development for multiple myeloma - hit or miss?
Important new preclinical data sets the scene for PDAC
Finding the sweetspot in early stage cancer drug development
Highlighting some outstanding research to take note of
Tackling intractable cancers with a novel and creative approach to the problem
A discussion of some of the key topics emerging in ER+ HER2- breast cancer
A next generation category of KRAS inhibitors are emerging - W2W4
Where we explain what to look for in 10 posters presented at AACR23
W2W4 on the TPD front
From one compound to many competitors following in their wake!
The ever evolving selective KRAS inhibitor & degrader space
Continuing our evaluation and exploration of another batch of early stage anti-cancer compounds either…
Half a dozen key early areas to watch out for
Going beyond the first past the post syndrome...
The evolving BMS-Celgene pipeline and what's coming next in new developmental twists
Ten emerging development areas to watch out for in oncology during 2023
A look at an evolving niche in hematologic malignancies
What started out as a short update from the recent EORTC-NCI-AACR (ENA / Triple Meeting) in Barcelona on…
Are there opportunities for combining small molecule inhibitors with protein degraders?
Can we overcome resistance checkpoint blockade with novel approaches to DDR?
Where is the TPD field likely headed with next generation approaches?
6 important and encouraging new developments to watch out for
What's the skinny on C4 Therapeutics and other TPD programs at AACR and ASCO?
5 key and novel early areas of development which stood out to us at AACR22
Going beyond both G12C and G12D to a plethora of new targets and combination approaches
Just because a pathway has been called undruggable doesn't always mean it will be so!
Hot topics to follow at AACR22
Some important new research which may stimulate a whole new class of anti-cancer therapies
The battle over AR antagonists and degraders rages on as new clinical data emerge
It's time for an update on novel protein degraders
The intriguing science behind a novel protein degrader platform
What to watch out for in 2022
A look at some cool science and novel strategies for tackling an intractable target
It's time to tackle some intractable targets in oncology and elsewhere...
Update on C4, Kymera, Novartis and Vividion
New research is emerging which may have an impact on future trial designs as well as combination partners and even different tumour types.
Who's going to win in the battle between protein degraders and small molecule inhibitors?
What can we learn from C4 Therapeutics monoDAC, CFT7455?
A look at the subtleties and nuances under the hood of the Arvinas PROTACs
13 talks at AACR21 caught our attention - which ones intrigued or dismayed - and why?
Emerging areas in cool new science around targeted therapies
Capturing attention in the crowded protein degradation niche
What to watch out for in the protein degradation niche
Getting to the centre of things with protein degradation
A rock around the myeloma clock through the eyes of a KOL - what stood out and what did not?
A critical look at the early stage BMS oncology pipeline
What's worth following on the targeted therapy front in breast cancer? A look pipelines and new indications from SABCS
A look at Kymera's protein degrader pipeline
Which hematology products in development produced the best data at ASCO 2020? We took a look at the key studies in lymphomas and myelomas to find out.
There are a few new developments of note to consider from ESMO Breast this weekend plus more to come at ASCO20 on Friday
An in-depth look at the emerging SERD landscape in ER+ metastatic breast cancer
What do we learn from the initial data with novel PROTAC technology?
Highlights and lowlights from Day 1 of JPM20
A look at off Broadway abstracts on early new product development and scientific findings of interest
How do we go about therapeutically targeting deep protein-protein interactions that can cause aberrant cancer activity? Here's one novel approach in early development...
